Oppenheimer reissued their buy rating on shares of Verastem (NASDAQ:VSTM) in a research report released on Sunday morning. The brokerage currently has a $15.00 price objective on the biopharmaceutical company’s stock.
Several other equities analysts also recently issued reports on the stock. Cantor Fitzgerald set a $17.00 price objective on shares of Verastem and gave the company a buy rating in a research note on Sunday. Cann reaffirmed a buy rating and set a $15.00 price target (up previously from $6.00) on shares of Verastem in a research note on Sunday. ValuEngine downgraded shares of Verastem from a sell rating to a strong sell rating in a research note on Friday, December 1st. Roth Capital began coverage on shares of Verastem in a research note on Friday, December 1st. They set a buy rating and a $12.00 price target on the stock. Finally, HC Wainwright reaffirmed a buy rating and set a $10.00 price target on shares of Verastem in a research note on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. Verastem currently has a consensus rating of Buy and a consensus price target of $10.03.
Shares of Verastem (NASDAQ VSTM) traded up $0.36 on Friday, hitting $4.33. 1,286,800 shares of the company traded hands, compared to its average volume of 760,211. The company has a current ratio of 3.12, a quick ratio of 3.12 and a debt-to-equity ratio of 0.06. Verastem has a fifty-two week low of $1.08 and a fifty-two week high of $5.71.
In related news, Director Timothy J. Barberich purchased 60,538 shares of the business’s stock in a transaction on Tuesday, December 5th. The shares were bought at an average price of $3.95 per share, with a total value of $239,125.10. Following the completion of the purchase, the director now directly owns 130,000 shares in the company, valued at approximately $513,500. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 6.51% of the company’s stock.
Large investors have recently bought and sold shares of the business. Artal Group S.A. purchased a new position in Verastem during the second quarter worth approximately $1,090,000. ClariVest Asset Management LLC purchased a new position in shares of Verastem in the 3rd quarter valued at $421,000. Alpine Woods Capital Investors LLC purchased a new position in shares of Verastem in the 2nd quarter valued at $109,000. Renaissance Technologies LLC raised its stake in shares of Verastem by 20.0% in the 1st quarter. Renaissance Technologies LLC now owns 1,226,600 shares of the biopharmaceutical company’s stock valued at $2,539,000 after acquiring an additional 204,400 shares during the period. Finally, EAM Investors LLC purchased a new position in shares of Verastem in the 3rd quarter valued at $2,092,000. 34.24% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Verastem (VSTM) Receives “Buy” Rating from Oppenheimer” was originally reported by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3088245/verastem-vstm-receives-buy-rating-from-oppenheimer.html.
Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.
Receive News & Ratings for Verastem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.